American University of Beirut

Effective rituximab treatment of B-cell PLL reported

Published in Managed Care Business Week, June 22nd, 2004

Effective treatment of B-cell PLL with rituximab has been reported.

Hematologists in Lebanon described "a patient with B-cell prolymphocytic leukemia (PLL) who was treated successfully with the monoclonal anti-CD20 antibody (rituximab)."

"The patient had recurrent infections due to relative neutropenia, secondary to bone marrow infiltration," noted Y.A. Mourad and coauthors at the American University in Beirut. "After treatment with monoclonal anti-CD20 antibodies (rituximab) 375 mg/m² weekly for 4 weeks, complete remission was obtained."

"It was documented by normalization of peripheral blood counts, disappearance of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Managed Care Business Week

Source: Managed Care Business Week (2004-06-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry